1/39
Looks like no tags are added yet.
Cell-free Fetal DNA
collected around 10wks, aka NIPT (noninvasive prenatal test)
present in maternal peripheral blood and sequenced by NGS and mapped to a reference chromosome
must sequence many millions of DNA fragments to ensure sufficient reads from specific chromosome to detect differences between aneuploid and euploid fetuses.
Biochemical methods used to…
analyze change in protein structure or function rather
than to search for potential point mutations.
useful in metabolic defects were actual protein
or amino acid alterations can be detected
ELISA
solid-phase enzyme immunoassay to detect the
presence of a substance in a liquid sample.
sample is attached to a surface and a
specific antibody (linked to an enzyme) is applied
over the surface so it can bind to the antigen.
substance with enzyme's substrate is
added and the reaction produces a detectable color change

HPLC (High-Performance Liquid Chromatography)
separate, identify, and quantify each component in a mixture.
pumps pass pressurized liquid solvent containing the sample mixture through a column filled with a solid adsorbent material
Each component in the sample interacts differently with the adsorbent material causing different flow rates for different components = separation of components as they flow out the column

Mass Spectrometer
converts molecules to ions that can be moved in an electric or magnetic field based on their charge and mass
Readout is a spectrum with the mass/charge
value on the x axis and abundance of the ion on
the y axis.
compound is identified by its characteristic spectrum or set of peaks.

MALDI (Matrix-assisted laser desorption/ionization)
ionization technique produces ions from large molecules for detection, sample mixed with matrix, coat surface, blast with laser to ionize, accelerate into mass spec.
MALDI-TOF (Matrix-assisted laser desorption/
ionization-time of flight)
MALDI without an electric field so ions are differentiated by time of flight, captures proteins on solid surface and eluted into detector
Smaller ions travel faster
can identify microorganisms for clinical testing

Cystic Fibrosis
Autosomal recessive defect is in the CF transmembrane regulator gene (CFTR), 7q31.2
Gene codes for a chloride channel membrane protein with the most common mutation: F508de, 3bp deletion removing Phe residue
CFTR protein
protein is anchored to the outer membrane of cells in the sweat glands, lungs, and pancreas and acts as a channel connecting the cytoplasm to the surrounding fluid.
Missing transport of ions across membrane = dehydration and thickening of mucous secretions
Protein cannot properly fold and leave the ER to perform functions as an ion channel
CF Pathway from Mutation to Syndrome
CFTR DNA
CFTR Protein
Ion transport
Altered secretions
Blocked ducts impaired mucosal defense
Infection/ Inflammation
CF
CF Clinical Testing
Immunoreactive trypsinogen (IRT)
Eary intervention
Sweat test
Target mutation analysis (array based)
Seq
Deletion Analysis
Immunoreactive trypsinogen (IRT)
standard newborn screening test for CF
A high level of IRT suggests possible CF and requires further testing.
Sweat test
used to determine whether a patient has CF (not for infants), in which current pushes medicine into skin to cause sweating and is collected to measure salt content
Canavan Disease Symptoms/Clinical Course
Neurodegenerative disease, symptoms appear in early infancy and progress rapidly
No cure for Canavan disease, treatment is symptomatic and supportive.
Canavan Disease Genetic Defect
defective ASPA gene, responsible aspartoacylase enzyme production (17p13.3)
E285A, Y231Ter - Ashkenazi Jewish populations,
A305E - non-Ashkenazi Jewish.
Canavan Disease Molecular Defect
gross deletions, null mutations = no aspartoacylase, and missense mutations = less active forms of aspartoacylase.
Although aspartoacylase is expressed widely throughout the body, its absence in the CNS leads to the specific build-up of NAA in the brain that causes demyelinization and other signs of the disease
Tay-Sachs Disease Symptoms/Clinical Course
fatal genetic lipid storage disorder, harmful quantities of fatty substance ganglioside GM2 build up in tissues and nerve cells in the brain.
Infants appear to develop normally for the first few months of life. but as nerve cells become distended with fatty material, deterioration of mental and physical abilities occurs.
no treatment
Tay-Sachs Disease Genetic Defect
Gene for Hexosaminidase A, alpha polypeptide, HEXA
variety of effects, from defective processing or subunit assembly to defective catalytic activity
Tay-Sachs Disease Clinical Testing
1. Prenatal and carrier testing
2. following initial diagnosis based on progressive weakness and loss of motor skill around 3-6 months
3. HEX A enzymatic activity
4. Targeted mutational analysis of most common mutations
5. Sequencing analysis if necessary
Phenylketonuria (PKU) Symptoms/Clinical Course
Inability to properly break down Phe, involved in melanin production so infants with the condition often have lighter skin, hair, and eyes
PKU Symptoms/Clinical Course
Treatment involves a diet that is low in Phe, particularly with child growth
Prognosis is excellent if the diet is followed otherwise severe retardation occurs if the disorder is untreated
PKU Genetic Defect
Defects in PAH gene codes for the enzyme phenylalanine hydroxylase, which converts phenylalanine to tyrosine
15 most common are point mutations and small deletions with R408W making up 50% of them
PKU Molecular Defect
Defects in the enzyme phenylalanine hydroxylase converts Phe to Tyr
If Phe from the diet is not processed effectively, Phe builds up toxic levels in the blood and tissues, and nerve cells in the brain are sensitive to Phe causing brain damage.
PKU Clinical Testing
Required screening test for all newborns in the US as part of newborn screening panel.
primary diagnosis based on a blood test for plasma Phe levels
most commonly diagnosed using a Guthrie card bloodspot heel prick
Confirmatory diagnosis by molecular testing.
PKU Clinical Testing
genetic testing of the PAH gene is used primarily for genetic counseling purposes to determine carrier status
• Sequencing: bi-directional sequencing of the coding regions (exons 1-13) and splice sites of the PAH gene.
• Reflexed to deletion/duplication testing if necessary
Glycogen Storage Disease Type I (GSDI) Symptoms/Clinical Course
inherited disorder caused by the buildup of glycogen in organs and tissues, especially liver, kidneys, and small intestines.
Symptoms typically appear around 3 or 4 months, when babies start to sleep through the night and do not eat as frequently as newborns.
Affected infants may have Hypoglycemia, lactic acidosis, hyperuricemia, and hyperlipidemia
GSDI Symptoms/Clinical Course
Older, untreated children have thin arms and legs short stature, osteoporosis, enlarged liver and kidneys
Treatment involves medical nutrition therapy to maintain normal glucose concentrations, prevent hypoglycemia, and provide optimal nutrition for growth and development.
GSDI Genetic Defect
G6PC (GSDIa) and SLC37A4 (GSDIb).
Mutations in G6PC account for approximately 80% and
mutations in SLC37A4 account for approximately 20%
GSDI Molecular Defect
enzyme G6P, catalytic subunit α, produced from the gene G6PC and the G6P transporter produced from SLC37A4 gene work together to break down G6P to glucose
if not broken down to glucose it is converted to glycogen and fat so it can be stored within cells, too much glycogen and fat stored within a cell can be toxic, damaging organs and tissues throughout the body
GSDI Clinical Testing
Abnormal blood/plasma concentrations of glucose, lactate, uric acid, triglycerides, and lipids.
Targeted mutation analysis, G6PC pathogenic variant p.Arg83Cys for Ashkenazi Jewish ancestry or other ancestry-specific mutations
Sequence analysis of G6PC, followed by sequence analysis of SLC37A4 if no G6PC pathogenic variants are identified and clinical indication of GSDI is strong.
Gaucher’s Disease Molecular Defect
Lysosomal Storage disease
Gaucher’s Disease Clinical Testing
demonstration of deficient beta-glucocerebrosidase enzyme activity in peripheral blood leukocytes or other nucleated cells. enzyme test called a beta-glucosidase leukocyte (BGL) test is the main tool used by physicians use to diagnose
Carrier testing: molecular testing
Targeted analysis for pathogenic variants, non-Jewish individuals with GD tend to be heterozygotes with one common and a unique pathogenic variant.
Sequence analysis of GBA, followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.
Hereditary Hemochromatosis (Type 1) Symptoms/Clinical Course
Defect in iron metabolism, with increased iron absorption from the diet
Eventual damage to tissues and organs: cirrhosis, cardiomyopathy, Diabetes, Hypogonadism
Hereditary Hemochromatosis (Type 1) Symptoms/Clinical Course
Symptoms of iron overload often diagnosed in men 40 and 60 and women after 60 (after menopause).
Diet greatly affects age of onset and severity.
Along with therapuetic blood removal, symptoms can be controlled by diet.

Hereditary Hemochromatosis (Type 1) Genetic Defect
Mutation in HFE gene (6p21.3)
• p.Cys282Tyr, 80% of clinical diagnosis.
• p.His63Asp (H63D)
• p.Ser65Cys (S65C)
Hetero or homozygosity of H63D and S65C with C282Y
Hereditary Hemochromatosis (Type 1) Molecular Defect
HFE protein interacts with other proteins on the intestinal cell surface to detect the amount of iron in the body.
When transferrin receptor 1 is bound to transferrin/Fe, signaling triggers a response of iron entering liver cells and when HFE protein is bound to transferrin receptor 1, the receptor cannot bind to transferrin/Fe.
When HFE protein is mutated, it doesn’t repress iron uptake in liver cells and too much iron moves into the liver.

Hereditary Hemochromatosis (Type 1) Clinical Testing
Biochemical testing finding elevated transferrin-iron saturation >45% and serum ferritin concentration > upper limit of normal
Confirmatory molecular testing for common variants in HFE
• LabCorp- PCR-RFLP
• Invitae- HH NGS 5 gene panel
• Multiplex PCR
Most people with the C282Y or H63D HFE gene variants develop hemochromatosis symptoms. This is a result of
high penetrance
if a disease phenotype is frequently present with the DNA variant, then the variant is said to have a high penetrance. Other conditions, such as iron loss or glycogen accumulation, are phenotypes that may or may not accompany the hemochromatosis (too much iron). Lifestyle and alcohol intake are behaviors that might affect susceptibility to diseases in general.
Bead array technology is most appropriate for what metabolic disorder?
CF, bead arrays detect multiple SNVs such as those found in cystic fibrosis
Variants in this gene encoding a transmembrane conductance regulator result in severe lung damage.
CFTR, cystic fibrosis is caused by loss of function of the CF transmembrane conductance regulator encoded by the CFTR gene (7q31.2)